v3.23.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses    
Research and development $ (21,528,338) $ (9,114,687)
Selling, general and administrative (6,154,319) (1,318,033)
Loss from operations (27,682,657) (10,432,720)
Change in fair value of derivative liabilities (2,194,500) 0
Financial investment income 3,254,400 63,381
Other financial gain/(loss), net 1,024,490 359,331
Loss before income taxes (25,598,267) (10,010,008)
Income tax expense (173,715) 0
Net loss $ (25,771,982) $ (10,010,008)
Net loss per share basic (in dollars per share) $ (0.09) $ (0.05)
Net loss per share diluted (in dollars per share) $ (0.09) $ (0.05)
Weighted-average number of shares outstanding – basic (in shares) 275,494,021 220,000,000
Weighted-average number of shares outstanding – diluted (in shares) 275,494,021 220,000,000

Source